Clinical trial · no report yet · Phase 2
NAUTIKA1
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- NCT04302025 ↗
- Recruiting
- Genentech, Inc.
- 34 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 20 | |
| YouTube | 10 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Alectinib; Entrectinib; Vemurafenib; Cobimetinib; Pralsetinib; Atezolizumab; SBRT; Resection; Chemotherapy; Divarasib
- Arms
- ALK Cohort (Enrolment Closed) · Experimental
- ROS 1 Cohort (Enrolment Closed) · Experimental
- NTRK Cohort (Enrolment Closed) · Experimental
- BRAF Cohort (No Participants Enrolled, Cohort Closed) · Experimental
- RET Cohort (Cohort closed) · Experimental
- PD-L1 Cohort (Enrolment Closed) · Experimental
- KRAS G12C Cohort · Experimental
- Enrollment
- 99 (estimated)
- Primary outcomes
- Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)
- Checkpoint Inhibitor (CPI) Cohort: Pathological Complete Response (pCR)
- KRAS G12C Cohort: Percentage of Participants With 3-5 Grade Adverse Events (AEs)
- KRAS G12C Cohort: Percentage of Participants Without Delays of Surgery due to Treatment-related AEs as Reported by the Investigator
- Sponsor
- Genentech, Inc.
- Start
- Nov 6, 2020
- Primary completion
- Nov 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04302025 · updated Sep 10, 2026